Evotec has entered into an integrated research collaboration with the Leukemia & Lymphoma Society (LLS). Evotec will support one of LLS's Screen-to-Lead Programs (SLP).
Evotec partners with LLS to support selected programs and principal investigators with resources for high-throughput screening and optimization of small molecules into drug-like compounds. Evotec delivers an industrialized, comprehensive and unbiased drug discovery infrastructure to support innovation efficiency as part of a fully integrated solution.
